Is CareBareRX legit and worth it?
CareBareRX is a real GLP-1 telehealth provider; we read its site and scored it 3.0/5 in our independent review (Use Caution). Biggest plus: Both brand-name (Ozempic) and compounded GLP-1 options available. Watch-out: No Trustpilot reviews yet.
Scorecard: strongest in Access (3.9/5) and Clinical Quality (3.5/5); weakest in Reputation (1.0/5) and Trust & Transparency (2.0/5).
Medications
Compounded, Ozempic (as entered 11 April 2026; capture date not recorded)
Monthly Cost
$199 – $705 (as entered 11 April 2026; capture date not recorded)
Speed to Start
Moderate
Trustpilot
Not yet rated (as recorded April 2026; not re-checked)
Prices and medications in this review are as entered in our research on 11 April 2026 (the date we captured them was not recorded), unless a line is marked otherwise, and have not been re-checked since. Note added 13 October 2026.
Corrected 14 October 2026: this review previously gave a Better Business Bureau rating or listing status. We kept no record of where it came from, so it has been removed. Trustpilot figures in this review are as recorded in April 2026 and have not been re-checked.
About CareBareRX
CareBareRX is a lifestyle-focused telehealth platform founded in 2025 that offers treatments across weight loss, hair growth, and sexual health. Their GLP-1 program includes both compounded medications and brand-name Ozempic, delivered through oral and subcutaneous formats — giving patients flexibility in treatment approach.
Monthly pricing ranges from $199 to $705, a wide spread that reflects the gap between compounded and brand-name options. The platform claims high provider quality, but the clinical program lacks the depth of top-tier competitors — no lab testing and no dietitian access are included, and ongoing support is rated low.
The biggest concern with CareBareRX is the near-total absence of external validation. There are no Trustpilot reviews, and the platform was only founded in 2025. Cost transparency is rated low, which makes it difficult for patients to understand the full financial commitment before signing up.
Trust and compliance transparency is also rated low. For a platform selling compounded injectable medications, the lack of publicly disclosed pharmacy partners and unknown Certificate of Analysis (CoA) status raises questions about sourcing quality. The brand’s multi-category approach (weight loss + hair + sexual health) suggests a generalist model rather than GLP-1-focused clinical expertise.
CareBareRX may appeal to patients looking for a one-stop telehealth platform across multiple health concerns, but the lack of reputation data and clinical depth means patients should proceed with clear expectations and do additional due diligence.
CareBareRX GLP-1 Medications
Screenshot of CareBareRX, captured by 11 April 2026
Screenshot of CareBareRX, captured by 11 April 2026
Screenshot of CareBareRX, captured by 11 April 2026
Screenshot of CareBareRX, captured by 11 April 2026
Screenshot of CareBareRX, captured by 11 April 2026
At a Glance
Medications Offered
Compounded, Ozempic (as entered 11 April 2026; capture date not recorded)
Both
Cost & Insurance
- Monthly: $199 – $705 (as entered 11 April 2026; capture date not recorded)
- 6-month estimate: $1200 – $4230 (as entered 11 April 2026; capture date not recorded)
- Insurance: No
- Self-pay: Yes
Clinical Features
- Lab testing: No
- Dietitian access: No
Delivery & Access
- Format: Both (Oral and Subcutaneous)
- Nationwide telehealth: Yes
- Speed: Moderate
- Spanish-speaking providers: Not available
What the CareBareRx Intake Looks Like
We walked through CareBareRx’s full GLP-1 intake ourselves, from the identity-first opening screen through the contraindications multi-select to the treatment-selection page that surfaces both compounded options and brand-name Ozempic. Here’s what an actual prospective patient encounters before being prescribed.
/ 10
A transparent contraindications multi-select with Bipolar Disorder and Schizophrenia named explicitly, MTC + MEN2 personal AND family history as separate items, hypoglycemia as a discrete checkbox, modern MASLD/MASH terminology, and free-text allergies and surgeries lists. Knocked down by no validated PHQ, no severity grading on eating disorders, no opiate/alcohol breakdown, no BP/HR range reading, and current-meds Yes/No only.
/ 10
Moderate. CareBareRx collects first name, last name, email, and gender on the very first screen — meaningfully more identity-up-front than peer platforms that run the questionnaire anonymously. Approve-first-charge applies at the plan-selection step, but the $80 fee disclosure contradicts itself between the verification stage and the final payment-page attestation.
The 5 Stages
Clinical Safety Screens Performed
The intake doesn’t use a validated PHQ-2 or PHQ-9 depression screen and doesn’t ask about self-harm. Bipolar Disorder and Schizophrenia are listed as contraindications, but there is no separate depression checkbox or severity grading for any mental-health condition. Eating disorders are checkbox items (anorexia or bulimia) rather than a dedicated screen. Substance use is collapsed into a single “Active Substance Abuse Disorder” checkbox — no opiate or alcohol breakdown. There is no actual blood pressure or heart-rate range, only checkbox items. Current medications are captured as a Yes/No only with no follow-up list. There’s no diet or exercise history depth, sex is collected as a binary Male / Female only, and no ID upload or phone OTP is required.
CareBareRx surfaces the $80 telehealth-consultation fee in two different ways during the flow, and the two disclosures contradict each other. At the verification stage, the on-screen note reads: “$80 consultation fee will apply only if your prescription is approved and you choose not to proceed with treatment. The consultation is free if you move forward with purchasing your prescription.” But on the final payment page, the mandatory attestation checkbox reads: “There is an $80 Telehealth consultation fee that will be charged regardless of whether I receive a prescription.” Patients should not assume the conditional disclosure is the binding one — the payment-page attestation is the language they’re consenting to. The plan-selection page does say “Payment will not be processed until approval is made,” so the medication itself is approve-first-charge, but the consultation-fee mechanic is unclear from the visible flow alone.
Source: GLP-1.Reviews editorial walkthrough on April 30, 2026. We completed every screen of the CareBareRx weight-loss intake using a representative GLP-1 candidate persona and stopped before submitting any payment information.
Opens carebarerx.com in a new tab.
Start your GLP-1 weight loss journey with CareBareRX today
Medical Disclaimer: This review is for informational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs that should only be used under the supervision of a licensed healthcare provider. Individual results may vary.
Editorial Independence: GLP-1.Reviews maintains full editorial independence. We read providers’ own pages and public records and publish what we find, with the date we checked.
Corrected 13 October 2026: this review showed a “Verified Provider” badge and said our scores were “based on verified data and standardized criteria”. Neither described a check we had done, so both have been removed.
